CRO expands oncology, adds functional service provider capabilities, strengthens global reach, and accelerates technology to enhance customer value
Worldwide Clinical Trials, a leading global contract research organization, has finalized its acquisition of Catalyst Clinical Research LLC, a specialized oncology CRO and functional service provider. This strategic combination brings together two organizations with complementary strengths in oncology, biometrics, and FSP solutions, significantly enhancing Worldwide’s ability to serve biopharma clients across the globe. The merger expands Worldwide’s workforce to approximately 4,400 employees in over 70 countries, creating a stronger, more versatile clinical research platform.
Health Technology Insights: Ambience Healthcare Teams With MultiCare on AI Platform Rollout
Alistair Macdonald, Chief Executive Officer of Worldwide, highlighted that the addition of Catalyst strengthens the company’s capabilities intentionally and strategically. He explained that integrating Catalyst’s expertise in early phase oncology and its flexible FSP model improves Worldwide’s scientific depth, operational agility, and therapeutic reach across oncology, neuroscience, rare disease, and internal medicine. Macdonald added that the expanded technology platforms and global site network will allow clients to execute clinical programs more efficiently, transparently, and with greater flexibility.
Health Technology Insights: Integrity Health Cuts Costs 16 Percentage Using Lightbeam Health Platform
Matt Jennings, Executive Chairman of Worldwide and Senior Operating Partner at Kohlberg, the majority owner of the company, stated that the acquisition enhances Worldwide’s oncology portfolio and global footprint. He noted that Catalyst’s scientific expertise, technology, and established biotech relationships are an ideal fit and reinforce the strategy of building a technology-enabled and differentiated CRO.
Nik Morton, former President and CEO of Catalyst, who will join Worldwide as Executive Vice President, Chief Strategy and Transformation Officer, commented that joining Worldwide represents an exciting new chapter. He emphasized the cultural alignment between the teams and their shared commitment to scientific excellence, operational integrity, and a people-first approach. Nick Dyer, Catalyst’s former Chairman of the Board, also joins Worldwide’s Board of Directors.
An integration team has been established to ensure a smooth transition for employees, clients, and partners while leveraging the best practices of both companies to unlock growth and innovation opportunities. The acquisition was completed for an undisclosed amount.
Worldwide is a portfolio company of Kohlberg, based in Mount Kisco, New York, which invests in healthcare and service companies. Catalyst was previously a portfolio company of QHP Capital, L.P., based in Research Triangle Park, North Carolina, which focuses on life sciences and pharmaceutical services. BofA Securities served as exclusive advisor to Catalyst, and Smith Anderson provided legal counsel. Greenberg Traurig, LLP served as legal counsel to Worldwide.
Health Technology Insights: Lōkahi Therapeutics Welcomes UGA Fellows to ai² Futures Lab
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
